Cancer SurvivorNCT06814977
An Acupuncture Study for Cancer Survivors With Joint Pain
A study testing Acupuncture in people with Cancer Survivor, run by Memorial Sloan Kettering Cancer Center at 2 sites in United States.
Trial summary
The purpose of this study is to see whether acupuncture is a practical (feasible) treatment for cancer survivors with joint pain. Read more about this study
- Who is it for?
- Ages 18 years and olderHealthy volunteers can take part
- Conditions the study is for
- Cancer Survivor
- What is being tested?
- Acupuncture
- Type of treatment
- Surgery or procedure
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 60 participants
- Where
- 2 sitesUnited States
- Study dates
- 31 Jan 2025to 30 Jun 2028
- Phase
- Interventional
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Who may be able to join
- English- or Spanish-speaking adults
- Non white or Hispanic women with a prior cancer diagnosis
- Stable oncological disease or no evidence oncological of disease per clinical documentation or clinician assessment
- Worst pain rated ≥4 on a 0-10 scale in the preceding week
- ≥15 days with pain in the past 30 days
- Pain lasting ≥1 month
- Willing and able to complete questionnaires and other study activities
- Willing and able to provide informed consent for the trial
Who cannot join
- Completed active treatment (chemotherapy, surgery, radiation, transplantation) <4 weeks prior to study
- Maintenance therapies are allowed
- Pain attributed to inflammatory arthritis (e.g., rheumatoid arthritis, gout)
- Other non-musculoskeletal pain syndromes (eg, headache, visceral abdominal pain, neuropathic pain) can be present as comorbid conditions if the patient reports musculoskeletal pain as the primary source of pain
- Procedures involving affected joints within the last month or planned in the next 14 weeks
- Acupuncture use for pain in the past three months
- Implanted electronic device (e.g., pacemaker)
Trial locations and contacts
2 sites in 1 country. Contact the study team or a site near you to ask about taking part.
Pamela Drullinsky, MD contact
United States2 sites, 2 recruiting
- Recruiting
Memorial Sloan Kettering Cancer Center (All protocol activites)
New York, New York, 10065
Kevin Liou, MD, 646-608-8563
- Recruiting
Jamaica Hospital Medical Center
Richmond Hill, New York, 11418
Rosa Nouvini, MD, 718-206-6000
About this study
Official title: Researching the Implementation of Acupuncture for Chronic Musculoskeletal Pain in Diverse Underserved Cancer Survivors (ReIMAGINE)
The purpose of this study is to see whether acupuncture is a practical (feasible) treatment for cancer survivors with joint pain.
- Conditions
- Cancer Survivor
- Being tested
- Acupuncture
- Keywords
- history of cancer, acupuncture, cancer, 24-305
- Medical subject headings
- Neoplasms
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
AcupunctureProcedure or surgery
Acupuncture is a non-pharmacological intervention that does not involve the use of any therapeutic agents or devices. Participants will receive 10 weekly treatments over 10 weeks.
| Study group | Role | What they receive |
|---|---|---|
| Acupuncture | Experimental | Participants will receive 10 weekly acupuncture treatments over 10 weeks. Receives: Procedure: Acupuncture |
| Usual Care | No intervention | Participants will receive standard medical care, including pain medications and other treatments |
What is being measured
The primary outcome is the main question the study is designed to answer.
Study feasibility as measured by rates of enrollment
The primary purpose of this study is to determine the feasibility of studying an acupuncture intervention for chronic musculoskeletal pain in racially/ethnically diverse, community-based cancer survivors.
Measured: 1 year
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted7 Feb 2025
- Study start31 Jan 2025
- Primary completion30 Jun 2028 (estimated)
- Study completion30 Jun 2028 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Cancer SurvivorStudies of the same condition, open and under way.
- More trials run by Memorial Sloan Kettering Cancer CenterThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Non-randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 60 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Kevin Liou, MD, Principal investigator, Memorial Sloan Kettering Cancer Center
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06814977
- Sponsor's protocol ID
- 24-305
- Status last verified
- Oct 2026
- First submitted
- 3 Feb 2025
- Last updated
- 15 Oct 2026
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Yes: Memorial Sloan Kettering Cancer Center supports the international committee of medical journal editors (ICMJE) and the ethical obligation of responsible sharing of data from clinical trials. The protocol summary, a statistical summary, and informed consent form will be made available on clinicaltrials.gov when required as a condition of Federal awards, other agreements supporting the research and/or as otherwise required. Requests for deidentified individual participant data can be made beginning 12 months after publication and for up to 36 months post publication. Deidentified individual participant data reported in the manuscript will be shared under the terms of a Data Use Agreement and may only be used for approved proposals. Requests may be made to: crdatashare@mskcc.org.